Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. develops and commercializes regenerative biomaterial products for wound care, burn and surgical applications. Its updates center on placental allografts and related advanced wound care technologies, including AMNIOFIX, CHORIOFIX and G4Derm Plus, as the company adds product configurations, distribution rights and clinical evidence for complex wound management.
Company news also covers operating results for the Wound and Surgical businesses, reimbursement-driven market conditions, cost-reduction actions, investor presentations, conference participation and capital actions such as share repurchase authorization.
MIMEDX reported solid Q1 2025 financial results with net sales of $88 million, marking a 4% year-over-year growth. The company achieved GAAP net income of $7 million and earnings per share of $0.05.
Key highlights include:
- Surgical products showed strong 16% growth, driven by AMNIOEFFECT and HELIOGEN
- Wound products experienced a slight 2% decline
- Gross margin was 81%, down from 85% in the prior year
- Adjusted EBITDA reached $17 million, representing 20% of net sales
- Cash position of $106 million as of March 31, 2025
CEO Joseph H. Capper expressed disappointment over LCD delays but announced plans to bridge gaps with new products like CELERA. The company reaffirmed its 2025 outlook, expecting high single-digit net sales growth and Adjusted EBITDA margin above 20%. Long-term goals include achieving low double-digit annual net sales growth.
MIMEDX Group (Nasdaq: MDXG) has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company will disclose its operating and financial results for Q1 2025 (ended March 31) after market close on Wednesday, April 30, 2025.
The senior management team will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day. Investors can access the call through dedicated U.S. (877-407-6184) and International (201-389-0877) lines using Conference ID 13752696. A replay of the webcast will be available on www.mimedx.com for approximately 30 days following the event.
MIMEDX (NASDAQ: MDXG) has announced its participation in three major industry conferences to showcase its latest scientific and clinical data for Advanced Wound Care and Surgical Solutions. The company will be present at:
1. MedStar Georgetown University Hospital's Diabetic Limb Salvage Conference (April 10-12, 2025) featuring a sponsored lunch symposium on limb salvage strategies
2. Symposium on Advanced Wound Care (SAWC) Spring 2025 (April 30-May 4, 2025) including a sponsored lunch symposium on wound healing
3. Digestive Disease Week (DDW) 2025 (May 3-6, 2025) featuring an oral presentation on hospital readmissions and anastamotic leaks in colorectal surgery
CEO Joseph H. Capper emphasized the company's commitment to innovation and expanding their clinical evidence base, particularly highlighting their expansion into gastrointestinal surgery applications.
MIMEDX (Nasdaq: MDXG) has announced its participation in the TD Cowen 45th Annual Health Care Conference, scheduled for March 3-5, 2025, at the Boston Marriott Copley Place. The company's senior management will deliver a presentation on Tuesday, March 4, 2025, at 11:10 AM ET.
The conference will feature presentations, fireside chats, and panel discussions focused on various aspects of the healthcare industry, moderated by TD Cowen research team members. Institutional investors can arrange meetings with MIMEDX senior management through their TD Cowen representatives.
A live webcast of the presentation will be accessible through the Events page in the Investors section of MIMEDX's website, with a replay available after the event.
MIMEDX (NASDAQ: MDXG) reported strong financial results for Q4 and full year 2024. Fourth quarter net sales grew 7% year-over-year to $93 million, while full-year net sales increased 9% to $349 million.
Q4 highlights include GAAP net income of $7 million ($0.05 per share) and Adjusted EBITDA of $20 million (21% of net sales). Gross margin was 82% for Q4 2024, with adjusted gross margin at 84%. The company maintained strong cash position with $104 million in cash and cash equivalents as of December 31, 2024.
Looking ahead to 2025, MIMEDX expects high single-digit net sales growth and Adjusted EBITDA margin above 20%. Long-term outlook projects low double-digit annual net sales growth with continued Adjusted EBITDA margin exceeding 20%.
MIMEDX Group (Nasdaq: MDXG) has announced its upcoming fourth quarter and full year 2024 financial results release, scheduled for after market close on Wednesday, February 26, 2025. The company's senior management team will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results.
Investors can access the conference call through a webcast or by phone, with separate dial-in numbers provided for U.S. (877-407-6184) and international investors (201-389-0877). A replay of the webcast will be available on the MIMEDX website for approximately 30 days following the event.
MIMEDX (NASDAQ: MDXG) has filed a patent infringement lawsuit against Surgenex in the U.S. District Court for the District of Arizona. The lawsuit alleges that several of Surgenex's placental allograft products infringe on MIMEDX's patents, seeking permanent injunctive relief and monetary damages. This is the second lawsuit against Surgenex, following earlier litigation regarding alleged corporate raiding and unfair competitive practices. MIMEDX, holding over 70 patents in the placental allograft category, plans to expand its investigation into potential patent infringements by other competitors amid the increasing number of skin substitutes entering the market.
MIMEDX Group (Nasdaq: MDXG) has announced its senior management's participation in three upcoming investor conferences in December 2024. The schedule includes:
- Mizuho Health Care Conference on Wednesday, December 11, featuring one-on-one sessions in New York, NY
- Northland Growth Conference on Thursday, December 12, with virtual one-on-one sessions
- Stifel MedTech West Coast Bus Tour on Thursday, December 12, offering one-on-one sessions in Palo Alto, CA
Interested investors can arrange meetings with MIMEDX senior management through their respective Mizuho, Northland Capital, or Stifel representatives.
MIMEDX Group (NASDAQ: MDXG) announces significant changes to Local Coverage Determinations (LCDs) for skin substitute grafts, effective February 12, 2025. The revised LCDs include key modifications: patient treatment applications increased from 4 to 8, and treatment duration extended from 12 to 16 weeks. Over 200 unproven skin substitutes will no longer be covered, while MIMEDX's EPIFIX® and EPICORD® remain on the covered products list. The company highlights that Medicare spending on skin substitutes has reached over $1 billion per month, representing a 20-fold increase over five years, which these changes aim to address.
MIMEDX Group (NASDAQ: MDXG) has announced its senior management's participation in two upcoming investor conferences in New York. The company will attend the Stifel Healthcare Conference 2024 on Monday, November 18, with a webcast scheduled for 9:45 AM ET, and the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19. Investors interested in meeting with MIMEDX management at these events should contact their Stifel or Craig-Hallum representatives.